CEL-SCI Corporation
https://cel-sci.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CEL-SCI Corporation
Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval
The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.
Merck & Co. Drops Kelun Claudin 18.2 ADC But Exercises Bispecific Option
The changes mark the second major revision to the 2022 antibody-drug conjugate-focused alliance between the US and Chinese firms, which is now focusing on ADCs against Trop2, Nectin-4 and other undisclosed targets. Meanwhile, the results from other trials with Claudin 18.2 ADCs have used varying definitions of high expression, with differing results.
Unilabs Signs Multi-Year Deal With C2N To Expand Alzheimer’s Test In Europe And Beyond
Unilabs and C2N Diagnostics signed a multi-year agreement that will expand access to C2N’s Alzheimer’s tests in Europe and other countries.
China Biotech Podcast: Going Global, IPO Status, Shanghai New Stimulus Policy
RNK Pharma founder and CEO Yaning Wang joins Brian Yang to discuss the latest biopharma stimulus policies offered by Shanghai and the globalization of China biotech. Dexter Yan also talks about China biotech initial public offering trends in the first half of this year.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Vaccines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice